NanoGuardian and Altegrity Risk to deliver closed-loop supply chain protection
Technology detects counterfeit medicines in the supply chain
NanoGuardian, a division of US firm NanoInk, has agreed that Altegrity Risk International (ARI) of New York City will be its security partner in delivering a technology to pharmaceutical manufacturers that detects counterfeit medicines in the supply chain.
NanoGuardian's Closed-Loop Protection Programme works with NanoEncryption technology and uses a statistical modelling system with pharmacy auditing to identify counterfeit or illegal pharmaceuticals.
‘NanoGuardian is committed to forging relationships with best-of-class partners in our effort to protect patients and brands. We are very excited to announce another such partnership with ARI, a global leader in corporate security with significant experience in the pharmaceutical space,’ said Dean Hart, executive vice president of NanoGuardian.
Hart said on-dose security technologies, such as NanoGuardian's NanoEncryption technology, that remain with every dose indefinitely and defy counterfeit packaging, are necessary to protect patients and brands from counterfeit drugs. The Closed-Loop Protection Programme provides an additional level of protection.
NanoEncryption works directly on capsules, tablets, vial caps, and single-use syringes to provide a layered security of overt, covert, and forensic features. The overt and covert security features allow dose-level authentication at any point in a manufacturer's supply chain, while the forensic and nano-scale NanoCodes provide tracing information on each dose.
